RS60226B1 - Stabilne vodene formulacije adalimumaba - Google Patents

Stabilne vodene formulacije adalimumaba

Info

Publication number
RS60226B1
RS60226B1 RS20200310A RSP20200310A RS60226B1 RS 60226 B1 RS60226 B1 RS 60226B1 RS 20200310 A RS20200310 A RS 20200310A RS P20200310 A RSP20200310 A RS P20200310A RS 60226 B1 RS60226 B1 RS 60226B1
Authority
RS
Serbia
Prior art keywords
adalimumab
buffer
stability
concentration
formulations
Prior art date
Application number
RS20200310A
Other languages
English (en)
Serbian (sr)
Inventor
Mark Manning
Robert W Payne
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50237778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS60226(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of RS60226B1 publication Critical patent/RS60226B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
RS20200310A 2012-09-07 2013-09-06 Stabilne vodene formulacije adalimumaba RS60226B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261698138P 2012-09-07 2012-09-07
US201361769581P 2013-02-26 2013-02-26
US201361770421P 2013-02-28 2013-02-28
EP13835291.9A EP2892550B1 (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab
PCT/US2013/058618 WO2014039903A2 (en) 2012-09-07 2013-09-06 Stable aqueous formulations of adalimumab

Publications (1)

Publication Number Publication Date
RS60226B1 true RS60226B1 (sr) 2020-06-30

Family

ID=50237778

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200310A RS60226B1 (sr) 2012-09-07 2013-09-06 Stabilne vodene formulacije adalimumaba

Country Status (31)

Country Link
US (39) US20140186361A1 (enExample)
EP (2) EP3701968A1 (enExample)
JP (3) JP6463268B2 (enExample)
KR (3) KR102362829B1 (enExample)
CN (1) CN104768576A (enExample)
AR (1) AR092470A1 (enExample)
AU (3) AU2013312300A1 (enExample)
BR (1) BR112015004984A2 (enExample)
CA (2) CA2884182C (enExample)
CL (1) CL2015000574A1 (enExample)
CY (1) CY1123407T1 (enExample)
DK (1) DK2892550T3 (enExample)
DO (1) DOP2015000051A (enExample)
EA (2) EA029215B1 (enExample)
EC (1) ECSP15013227A (enExample)
ES (1) ES2784861T3 (enExample)
HR (1) HRP20200434T1 (enExample)
HU (1) HUE049282T2 (enExample)
IL (2) IL237583B (enExample)
LT (1) LT2892550T (enExample)
MX (1) MX2015003007A (enExample)
PE (2) PE20191815A1 (enExample)
PL (1) PL2892550T3 (enExample)
PT (1) PT2892550T (enExample)
RS (1) RS60226B1 (enExample)
SG (2) SG11201501715QA (enExample)
SI (1) SI2892550T1 (enExample)
SM (1) SMT202000147T1 (enExample)
TW (2) TWI698253B (enExample)
UY (1) UY35351A (enExample)
WO (1) WO2014039903A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101730694B1 (ko) 2012-03-07 2017-04-27 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
CA2926588C (en) 2013-10-16 2020-07-21 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3125928A4 (en) * 2014-04-02 2017-11-29 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of adalimumab
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) * 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP3050557A1 (en) 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
US20170189528A1 (en) 2014-06-10 2017-07-06 Meiji Seika Pharma Co., Ltd. Stable aqueous adalimumab formulation
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
TW201636047A (zh) * 2015-01-28 2016-10-16 麥博賽恩斯有限公司 抗－ＴＮＦ－α抗體之醫藥調配物
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
EP3256160A1 (en) * 2015-02-13 2017-12-20 Sanofi Stable liquid formulation for monoclonal antibodies
WO2016162819A1 (en) 2015-04-07 2016-10-13 Lupin Limited Stable aqueous pharmaceutical composition of anti-tnf alpha antibody
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11583584B1 (en) * 2015-10-28 2023-02-21 Coherus Biosciences, Inc. Stable protein compositions and methods of their use
BR112018014123A2 (pt) * 2016-01-12 2018-12-11 Dr. Reddy's Laboratories Limited formulação farmacêutica aquosa estável.
CA3013336A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2017147293A1 (en) 2016-02-23 2017-08-31 Eleven Biotherapeutics, Inc. Il-6 antagonist formulations and uses thereof
JP2019511531A (ja) * 2016-04-13 2019-04-25 メディミューン，エルエルシー 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace
US20180043020A1 (en) * 2016-04-20 2018-02-15 Coherus Biosciences, Inc. Method of reducing immunogenicity of drug products
TN2018000443A1 (en) 2016-06-30 2020-06-15 Celltrion Inc Stable liquid pharmaceutical preparation
US11236146B2 (en) * 2016-10-28 2022-02-01 Celltrion Inc. Stable pharmaceutical formulation
WO2018119142A1 (en) * 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11608357B2 (en) 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
EP3372242A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
EP3372241A1 (en) * 2017-03-06 2018-09-12 Ares Trading S.A. Liquid pharmaceutical composition
NZ757965A (en) * 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
WO2018184692A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2018184693A1 (en) * 2017-04-07 2018-10-11 Ares Trading S.A. Liquid pharmaceutical composition
WO2019060062A1 (en) * 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
US20210070850A1 (en) * 2017-09-20 2021-03-11 Alvotech Hf Pharmaceutical formulations for adalimumab
MX421763B (es) 2018-03-29 2025-03-14 Airway Therapeutics Inc Metodos y composiciones que comprenden proteina d tensoactiva (sp-d)
TW202042840A (zh) * 2019-01-11 2020-12-01 南韓商三星Ｂｉｏｅｐｉｓ股份有限公司 包含抗體的醫藥組成物、包含其的裝置、及其用途
JP7266108B2 (ja) * 2019-02-18 2023-04-27 イーライ リリー アンド カンパニー 治療用抗体製剤
WO2020187760A1 (en) * 2019-03-18 2020-09-24 Alvotech Hf Aqueous formulations of tnf-alpha antibodies in high concentrations
EP4021497A4 (en) * 2019-08-30 2023-09-06 Kashiv Biosciences, LLC NOVEL FORMULATION OF A HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODIES
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
EP4090368A1 (en) * 2020-01-13 2022-11-23 Aptevo Research and Development LLC Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
US20230173068A1 (en) * 2020-02-20 2023-06-08 Bio-Thera Solutions, Ltd. ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF
CA3169901A1 (en) * 2020-03-13 2021-09-16 Mi Gyeong Kim Pharmaceutical liquid composition having increased stability
CA3182368A1 (en) 2020-05-01 2021-11-04 Kashiv Biosciences, Llc An improved process of purification of protein
EP4153234A1 (en) * 2020-05-21 2023-03-29 Shilpa Biologicals Private Limited Pharmaceutical compositions comprising adalimumab
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
US20240158498A1 (en) * 2021-03-03 2024-05-16 Allakos Inc. Anti-siglec-8 antibody formulations
US20240366757A1 (en) * 2021-09-07 2024-11-07 Dr. Reddy’S Laboratories Limited Formulations of immune check point inhibitors or like
WO2023043232A1 (ko) * 2021-09-16 2023-03-23 주식회사 에이프로젠 항-TNFα 항체를 포함하는 약제학적 조성물
CN114788809B (zh) * 2022-01-25 2023-04-14 江苏广承药业有限公司 一种氯雷他定液体制剂
WO2023183898A1 (en) * 2022-03-24 2023-09-28 Arch Oncology, Inc. Formulations for anti-cd47 antibodies
WO2025038671A2 (en) * 2023-08-15 2025-02-20 Amgen Inc. Acidic buffered intravenous solution stabilizers for use in methods of treatment

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US5104651A (en) 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
KR100365171B1 (ko) 1994-08-08 2003-02-19 드바이오팜 에스.아. 약학적으로안정한옥살리플라티늄제제
IL114909A (en) 1994-08-12 1999-10-28 Immunomedics Inc Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6171576B1 (en) 1995-11-03 2001-01-09 Organix Inc. Dopamine transporter imaging agent
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0938334A4 (en) 1996-07-26 2004-12-15 Smithkline Beecham Corp IMPROVED METHOD FOR TREATING IMMUNE-MEDIATED SYSTEMIC DISEASES
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2190087T3 (es) * 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6171686B1 (en) 1997-10-03 2001-01-09 Marine Environmental Solutions, L.L.C. Synthetic aquatic structure
DK0917879T3 (da) 1997-11-22 2002-11-04 Roche Diagnostics Gmbh Forbedret fremgangsmåde til stabilisering af proteiner
WO1999037329A1 (en) 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
ES2421736T3 (es) 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
CN101333256A (zh) 1999-03-25 2008-12-31 艾博特股份有限两合公司 结合人il-12的人抗体及其生产方法
MXPA01010208A (es) 1999-04-09 2003-07-21 Johnson & Johnson Composiciones farmaceuticas de eritropoyetina.
AUPQ026799A0 (en) 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
JP5490972B2 (ja) 2000-08-04 2014-05-14 中外製薬株式会社 タンパク質注射製剤
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
JP4340062B2 (ja) 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
NZ530765A (en) 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases
EP1441589B1 (en) * 2001-11-08 2012-05-09 Abbott Biotherapeutics Corp. Stable liquid pharmaceutical formulation of igg antibodies
PL215168B1 (pl) 2002-02-27 2013-10-31 Immunex Corp Formulacja polipeptydowa
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040022792A1 (en) 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
US20060165733A1 (en) 2002-07-09 2006-07-27 Michael Betz Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2003287299A1 (en) 2002-11-01 2004-06-07 Bayer Healthcare Llc Process for concentration of macromolecules
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
WO2005063291A1 (ja) * 2003-12-25 2005-07-14 Kirin Beer Kabushiki Kaisha 抗体を含有する安定な水性医薬製剤
WO2006022599A1 (en) 2004-08-27 2006-03-02 Marian Metke Production method for exfoliated graphite, equipment for its production, exfoliated graphite and means of its use
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
PE20071063A1 (es) 2005-12-20 2007-10-24 Bristol Myers Squibb Co Formulaciones de proteinas estables
AU2007212147A1 (en) 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US20110130544A1 (en) * 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
KR101140483B1 (ko) 2007-05-02 2012-07-11 에프. 호프만-라 로슈 아게 단백질을 안정화시키는 방법
WO2009015345A1 (en) 2007-07-25 2009-01-29 Amgen Inc. Pharmaceutical compositions comprising fc fusion proteins
US20090151807A1 (en) 2007-08-07 2009-06-18 Davis Chanda Janese Container Insert for Zero Headspace
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
RU2473360C2 (ru) * 2007-11-30 2013-01-27 Эббот Лэборетриз Белковые композиции и способы их получения
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
WO2009073805A2 (en) 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
JP5808249B2 (ja) * 2008-10-20 2015-11-10 アッヴィ・インコーポレイテッド プロテインａアフィニティークロマトグラフィーを用いる抗体の単離および精製
JP2012510468A (ja) 2008-11-28 2012-05-10 アボット・ラボラトリーズ 安定な抗体組成物およびこれを安定させるための方法
WO2010066634A1 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Method for obtaining an excipient-free antibody solution
WO2010129469A1 (en) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
BR112012012080B1 (pt) 2009-11-20 2022-11-29 Biocon Limited Formulações de histidina-trealose do anticorpo t1h
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
KR101853981B1 (ko) * 2010-03-01 2018-05-02 사이토딘 인크. 농축 단백질 제형물 및 그의 용도
CN102946858B (zh) 2010-05-10 2015-09-30 英塔斯制药有限公司 含有免疫球蛋白Fc的多肽的液体制剂
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
CH703405B1 (de) 2010-07-05 2014-05-15 Melexis Tessenderlo Nv Magnetischer Winkelsensor.
JP6121903B2 (ja) * 2010-08-19 2017-04-26 ゾエティス・ベルジャム・エス・アー 抗ｎｇｆ抗体およびその使用
EA027353B1 (ru) * 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
HRP20161753T1 (hr) 2010-11-11 2017-02-10 Abbvie Biotechnology Ltd Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
US9453067B2 (en) 2011-04-20 2016-09-27 Sandoz Ag Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc
MX2013013437A (es) 2011-05-19 2013-12-06 Novartis Ag 4-amino-5-fluoro-3- [6- (4-metil-piperazin-1-il) -1h-bencimidazol-2-il] -1h-quinolin-2-ona parea usarse en el tratamiento de un carcinoma adenoide quistico.
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
US10995130B2 (en) 2011-07-01 2021-05-04 Biogen Ma Inc. Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
WO2013096835A1 (en) 2011-12-23 2013-06-27 Abbvie Inc. Stable protein formulations
KR101730694B1 (ko) 2012-03-07 2017-04-27 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
US20150150982A1 (en) 2012-06-12 2015-06-04 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150102042A1 (en) 2012-07-10 2015-04-16 Gary Matsch Air Purging Lid
TWI698253B (zh) 2012-09-07 2020-07-11 美商柯赫勒斯生物科學有限公司 阿達木單抗（ａｄａｌｉｍｕｍａｂ）之穩定水性調配物
EP2934587A4 (en) 2012-12-18 2016-08-03 Merck Sharp & Dohme Liquid formulations for an anti-TNF-alpha-antibody
CN102988984B (zh) 2012-12-21 2015-05-20 嘉和生物药业有限公司 增强稳定性的抗TNF-α人单克隆抗体的含水药物制剂
CN105358042B (zh) 2013-05-13 2018-05-29 恩多巧爱思股份有限公司 内窥镜端头位置视觉指示器和热量管理系统
US9681695B2 (en) 2013-07-31 2017-06-20 Sport Maska Inc. Helmet with chin cup

Also Published As

Publication number Publication date
US20180028657A1 (en) 2018-02-01
EA201590518A1 (ru) 2016-05-31
US20160256546A1 (en) 2016-09-08
US20160304601A1 (en) 2016-10-20
US20180140701A1 (en) 2018-05-24
TW202042841A (zh) 2020-12-01
US9707293B2 (en) 2017-07-18
US9757454B2 (en) 2017-09-12
US10799585B2 (en) 2020-10-13
US20160256545A1 (en) 2016-09-08
BR112015004984A2 (pt) 2017-07-04
HUE049282T2 (hu) 2020-09-28
US20180311350A1 (en) 2018-11-01
KR20210040470A (ko) 2021-04-13
US10772959B2 (en) 2020-09-15
US20190070292A1 (en) 2019-03-07
PE20150964A1 (es) 2015-07-25
EP3701968A1 (en) 2020-09-02
US20180028656A1 (en) 2018-02-01
ES2784861T3 (es) 2020-10-01
US9382317B2 (en) 2016-07-05
EP2892550A2 (en) 2015-07-15
US20170312361A1 (en) 2017-11-02
US10159732B2 (en) 2018-12-25
US20180043018A1 (en) 2018-02-15
WO2014039903A2 (en) 2014-03-13
CN104768576A (zh) 2015-07-08
US9731008B2 (en) 2017-08-15
US10688183B2 (en) 2020-06-23
JP2019069993A (ja) 2019-05-09
PE20191815A1 (es) 2019-12-27
US20150191538A1 (en) 2015-07-09
AU2013312300A1 (en) 2015-04-16
US10716854B2 (en) 2020-07-21
US10207000B2 (en) 2019-02-19
CA2884182C (en) 2022-06-14
SI2892550T1 (sl) 2020-11-30
US20180043019A1 (en) 2018-02-15
US20180311351A1 (en) 2018-11-01
US9731009B2 (en) 2017-08-15
US20180028653A1 (en) 2018-02-01
US20190070294A1 (en) 2019-03-07
US20160304599A1 (en) 2016-10-20
US9782479B2 (en) 2017-10-10
IL277652B (en) 2022-09-01
CL2015000574A1 (es) 2015-10-23
JP6463268B2 (ja) 2019-01-30
DOP2015000051A (es) 2015-05-31
KR102362829B1 (ko) 2022-02-15
JP2015527402A (ja) 2015-09-17
IL237583B (en) 2020-10-29
US20190070293A1 (en) 2019-03-07
US10155039B2 (en) 2018-12-18
US20180055929A1 (en) 2018-03-01
IL237583A0 (en) 2015-04-30
US9682145B2 (en) 2017-06-20
US10195275B2 (en) 2019-02-05
DK2892550T3 (da) 2020-03-30
US10159733B2 (en) 2018-12-25
EA201791717A1 (ru) 2018-03-30
US20180311349A1 (en) 2018-11-01
US10780163B2 (en) 2020-09-22
US9782480B2 (en) 2017-10-10
US20150182626A1 (en) 2015-07-02
US10786566B2 (en) 2020-09-29
US20180028654A1 (en) 2018-02-01
US20180028655A1 (en) 2018-02-01
UY35351A (es) 2014-08-29
CA3153799A1 (en) 2014-03-13
US20160256547A1 (en) 2016-09-08
US9808525B2 (en) 2017-11-07
US10286071B2 (en) 2019-05-14
AU2020202912A1 (en) 2020-05-21
US20160304600A1 (en) 2016-10-20
US20160303233A1 (en) 2016-10-20
US9724414B2 (en) 2017-08-08
JP6783845B2 (ja) 2020-11-11
SG11201501715QA (en) 2015-05-28
SMT202000147T1 (it) 2020-05-08
HK1210601A1 (en) 2016-04-29
US20150191539A1 (en) 2015-07-09
SG10201705668XA (en) 2017-08-30
EP2892550A4 (en) 2016-04-13
CY1123407T1 (el) 2021-12-31
CA2884182A1 (en) 2014-03-13
US20180021433A1 (en) 2018-01-25
US20160303235A1 (en) 2016-10-20
IL277652B2 (en) 2023-04-01
US9346880B2 (en) 2016-05-24
US20170072054A1 (en) 2017-03-16
TWI698253B (zh) 2020-07-11
US9770507B2 (en) 2017-09-26
AU2018208699A1 (en) 2018-08-16
US20190060455A1 (en) 2019-02-28
US10716853B2 (en) 2020-07-21
IL277652A (en) 2020-11-30
MX2015003007A (es) 2015-06-05
ECSP15013227A (es) 2016-01-29
US9737600B2 (en) 2017-08-22
EA029215B1 (ru) 2018-02-28
JP2021020930A (ja) 2021-02-18
US9724415B2 (en) 2017-08-08
PT2892550T (pt) 2020-03-27
US9340611B2 (en) 2016-05-17
EP2892550B1 (en) 2019-12-18
US20150190512A1 (en) 2015-07-09
US9340612B2 (en) 2016-05-17
HRP20200434T1 (hr) 2020-07-24
US10286072B2 (en) 2019-05-14
US9789185B2 (en) 2017-10-17
US20150190513A1 (en) 2015-07-09
US20160039926A1 (en) 2016-02-11
US20160303234A1 (en) 2016-10-20
US9861695B2 (en) 2018-01-09
US20180055930A1 (en) 2018-03-01
US20160031982A1 (en) 2016-02-04
US10772960B2 (en) 2020-09-15
US20160263226A1 (en) 2016-09-15
LT2892550T (lt) 2020-04-10
KR20220025196A (ko) 2022-03-03
AR092470A1 (es) 2015-04-22
US10716852B2 (en) 2020-07-21
KR20150047140A (ko) 2015-05-04
KR102238677B1 (ko) 2021-04-12
WO2014039903A3 (en) 2014-06-26
US20180311352A1 (en) 2018-11-01
PL2892550T3 (pl) 2020-07-27
TW201424749A (zh) 2014-07-01
US20140186361A1 (en) 2014-07-03
US10722579B2 (en) 2020-07-28

Similar Documents

Publication Publication Date Title
US10772960B2 (en) Stable aqueous formulations of adalimumab
HK40037264A (en) Stable aqueous formulations of adalimumab
HK1210601B (en) Stable aqueous formulations of adalimumab